1887

Abstract

Human papillomavirus (HPV) type 16 is the major cause of cervical carcinoma, the incidence of which is decreasing in western countries. In Finland the incidence is, however, increasing in women aged <40 years, but possible underlying changes in HPV-16 epidemiology are unknown. To assess incidence trends of HPV infections, paired sera from a random sample of 8000 women with two pregnancies/sera within 5 years, taken from the serum bank of the Finnish Maternity Cohort (1983–98), were analysed for HPV-6, -11 and -16 antibodies. For 23–31-year-old women, HPV-16 incidence increased over the period 1983–97. HPV-16 seroprevalence increased from 17 % in 1983–85 to 24 % in 1995–97, but HPV-6 and HPV-11 prevalence was stable at 9–12 % throughout the study period. Epidemic spread of the oncogenic HPV-16, but not the non-oncogenic HPV-types, throughout the 1980s and 1990s preceded an increase in the incidence of cervical carcinoma in fertile-aged Finnish women.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18995-0
2003-08-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/8/vir842105.html?itemId=/content/journal/jgv/10.1099/vir.0.18995-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam, V., Wang, Z., Lewensohn-Fuchs, I., Eklund, C., Schiller, J. T., Forsgren, M. & Dillner, J. ( 1998a; ). Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969–1989. Int J Cancer 76, 341–344.[CrossRef]
    [Google Scholar]
  2. af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. & Dillner, J. ( 1998b; ). Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177, 1710–1714.[CrossRef]
    [Google Scholar]
  3. Anttila, A., Pukkala, E., Söderman, B., Kallio, M., Nieminen, P. & Hakama, M. ( 1999; ). Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 83, 59–65.[CrossRef]
    [Google Scholar]
  4. Carter, J. J., Koutsky, L. A., Wipf, G. C., Christensen, N. D., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. ( 1996; ). The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174, 927–936.[CrossRef]
    [Google Scholar]
  5. Dillner, J., Kallings, I., Brihmer, C., Sikström, B., Koskela, P., Lehtinen, M., Schiller, J. T., Sapp, M. & Mårdh, P. A. ( 1996; ). Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173, 1394–1398.[CrossRef]
    [Google Scholar]
  6. Haavio-Mannila, E., Kontula, O. & Kuusi, E. ( 2001; ). Trends in Sexual Life. Working Papers E 10/2001. Helsinki: The Population Research Institute.
  7. IARC (International Agency for Research on Cancer) ( 1995; ). Human Papillomavirus. IARC Monographs, vol. 63: Lyon: IARC.
  8. Kibur, M., af Geijersstam, V., Pukkala, E. & 7 other authors ( 2000a; ). Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect 76, 13–17.[CrossRef]
    [Google Scholar]
  9. Kibur, M., Koskela, P., Dillner, J., Leinikki, P., Saikku, P., Lehtinen, M. & Hakama, M. ( 2000b; ). Seropositivity to multiple sexually transmitted infections is not common. Sex Transm Dis 27, 425–430.[CrossRef]
    [Google Scholar]
  10. Knekt, P. ( 1990; ). Serum Alpha-Tocopherol and Risk of Cancer. Series ML: 83, Helsinki: Publications of the Social Insurance Institution.
  11. Lehtinen, M., Dillner, J., Knekt, P. & 8 other authors ( 1996; ). Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case–control study. Br Med J 312, 537–539.[CrossRef]
    [Google Scholar]
  12. Lehtinen, M., Paavonen, J. & Vonka, V. ( 2002; ). Human papillomavirus infection of the cervix: its transmission, management during pregnancy and future vaccine developments. In Viral Infection in Pregnancy, pp. 169–178. Edited by G. Donders & B. Stray-Pedersen. New York: Elsevier.
  13. Sigurdsson, K. ( 1999; ). The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78, 478–485.[CrossRef]
    [Google Scholar]
  14. Vizcaino, A. P., Moreno, V., Bosch, F. X., Muñoz, N., Barros-Dios, X. M., Borras, J. & Parkin, D. M. ( 2000; ). International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86, 429–435.[CrossRef]
    [Google Scholar]
  15. Walboomers, J. M., Jacobs, M. V., Manos, M. M. & 7 other authors ( 1999; ). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12–19.[CrossRef]
    [Google Scholar]
  16. Wen, L. M., Estcourt, C. S., Simpson, J. M. & Mindel, A. ( 1999; ). Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 75, 312–316.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18995-0
Loading
/content/journal/jgv/10.1099/vir.0.18995-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error